Novel Gd Nanoparticles Enhance Vascular Contrast for High-Resolution Magnetic Resonance Imaging
Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-t...
Saved in:
| Published in | PloS one Vol. 5; no. 9; p. e13082 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
30.09.2010
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety.
To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T(1)) relaxivity, r(1), constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs.
The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. |
|---|---|
| AbstractList | Background
Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety.
Methodology/Principal Findings
To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T1) relaxivity, r1, constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs.
Conclusions/Significance
The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. Background Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety. Methodology/Principal Findings To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T.sub.1) relaxivity, r.sub.1, constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs. Conclusions/Significance The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety. To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T.sub.1) relaxivity, r.sub.1, constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs. The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. Background Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety. Methodology/Principal Findings To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T1) relaxivity, r1, constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs. Conclusions/Significance The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety.To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T(1)) relaxivity, r(1), constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs.The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety.BACKGROUNDGadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety.To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T(1)) relaxivity, r(1), constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs.METHODOLOGY/PRINCIPAL FINDINGSTo determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T(1)) relaxivity, r(1), constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs.The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases.CONCLUSIONS/SIGNIFICANCEThe novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety. To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T(1)) relaxivity, r(1), constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs. The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases. |
| Audience | Academic |
| Author | Bui, Tot Ho, Rodney J. Y. Zhang, Shanrong Maravilla, Kenneth Stevenson, Jeff Hoekman, John |
| AuthorAffiliation | 2 Department of Radiology, University of Washington, Seattle, Washington, United States of America 1 Department of Pharmaceutics, University of Washington, Seattle, Washington, United States of America Karolinska Institutet, Sweden |
| AuthorAffiliation_xml | – name: Karolinska Institutet, Sweden – name: 2 Department of Radiology, University of Washington, Seattle, Washington, United States of America – name: 1 Department of Pharmaceutics, University of Washington, Seattle, Washington, United States of America |
| Author_xml | – sequence: 1 givenname: Tot surname: Bui fullname: Bui, Tot – sequence: 2 givenname: Jeff surname: Stevenson fullname: Stevenson, Jeff – sequence: 3 givenname: John surname: Hoekman fullname: Hoekman, John – sequence: 4 givenname: Shanrong surname: Zhang fullname: Zhang, Shanrong – sequence: 5 givenname: Kenneth surname: Maravilla fullname: Maravilla, Kenneth – sequence: 6 givenname: Rodney J. Y. surname: Ho fullname: Ho, Rodney J. Y. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20927340$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk11r2zAUhs3oWNts_2BshsHGLpLpw9bHLgYldG2ga6HbeitkWXYUFCmz7LL--8qNU-JSxtCFxNHzniO9nHOcHDjvdJK8hWAGMYVfVr5rnLSzTQzPAIAYMPQiOYIcoylBAB_snQ-T4xBWAOSYEfIqOUSAI4ozcJSIS3-rbXpWppfS-Y1sWqOsDumpW0qndHojg-qsbNK5d20jQ5tWvknPTb2cXuvgbdca79IfsnY6KtM-5h6Ei7WsjatfJy8raYN-M-yT5Pf301_z8-nF1dlifnIxVYTDdop1xhTLKw0YZyWBOeMcyhxVipWV5oQVBSUVy7CiFNAiIzxXoNIlA4ghSnI8Sd5v826sD2LwJgiIIeMIQooisdgSpZcrsWnMWjZ3wksjHgK-qcXwe0FVkXHFNAEUZKwgnDHNECYgK6OlZZ_r21CtK9a6VLr3xo6Sjm-cWYra3wrEMwZg_9xPQ4LG_-l0aMXaBKWtlU77LgiaU0gJACSSH56Qz39uoGoZ329c5WNZ1ecUJxnFLCc4bpNk9gwVV6nXRsU-qkyMjwSfR4LItPpvW8suBLH4ef3_7NXNmP24xy61tO1y10xhDL7bN_rR4V0DRyDbAqrxITS6ekQgEP2c7OwS_ZyIYU6i7OsTmTKt7MtHR4z9t_ge_BAW6Q |
| CitedBy_id | crossref_primary_10_1002_jps_23773 crossref_primary_10_1016_j_xphs_2020_01_016 crossref_primary_10_1021_acsomega_4c08839 crossref_primary_10_1080_1061186X_2018_1433681 crossref_primary_10_1073_pnas_1406554111 crossref_primary_10_1116_1_4994286 crossref_primary_10_1039_c2jm30629h crossref_primary_10_1038_ncomms5712 crossref_primary_10_1039_C4NJ00571F crossref_primary_10_1016_j_molliq_2022_120628 crossref_primary_10_1021_acs_bioconjchem_9b00499 crossref_primary_10_1039_c3tb20521e crossref_primary_10_1002_chem_201501905 crossref_primary_10_1016_j_ejpb_2013_12_010 crossref_primary_10_1371_journal_pone_0034333 crossref_primary_10_1007_s00216_012_6217_y crossref_primary_10_1089_aid_2014_0210 crossref_primary_10_1016_j_ica_2020_119725 crossref_primary_10_1002_wnan_1198 crossref_primary_10_3390_ph12030137 crossref_primary_10_1016_j_coche_2013_11_006 crossref_primary_10_1016_j_xphs_2021_10_009 crossref_primary_10_1093_pnasnexus_pgac140 crossref_primary_10_1148_radiol_11110040 crossref_primary_10_1088_0031_9155_59_2_R65 crossref_primary_10_3390_ijms160511131 crossref_primary_10_1039_C6NJ03934K crossref_primary_10_1016_j_xphs_2020_02_010 crossref_primary_10_1038_srep15641 crossref_primary_10_1186_s11671_018_2695_y crossref_primary_10_1021_bc300605f crossref_primary_10_3762_bjnano_13_118 crossref_primary_10_1021_acsomega_0c03073 crossref_primary_10_1002_wnan_1170 crossref_primary_10_1111_j_1549_8719_2011_00137_x |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2010 Public Library of Science 2010 Bui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Bui et al. 2010 |
| Copyright_xml | – notice: COPYRIGHT 2010 Public Library of Science – notice: 2010 Bui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Bui et al. 2010 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0013082 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints (Gale in Context) Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Database ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Materials Science Database (NC LIVE) Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database ProQuest Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Gd-LNP for Better MRI |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1318921172 oai_doaj_org_article_7cb49c8e607048b6988e823604d193d2 PMC2948015 2924614331 A473856347 20927340 10_1371_journal_pone_0013082 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI 077390 – fundername: NINDS NIH HHS grantid: R01 NS039178 – fundername: NINDS NIH HHS grantid: NS 39178 – fundername: NIAID NIH HHS grantid: R01 AI077390 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RIG RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM PUEGO AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c691t-3e48c85fe0898d6158991a52fc8dfe968bb76f843c7707b4695c0fed802827653 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Jun 04 06:36:55 EDT 2023 Wed Aug 27 01:29:51 EDT 2025 Thu Aug 21 13:30:11 EDT 2025 Fri Jul 11 08:18:00 EDT 2025 Fri Jul 25 10:34:45 EDT 2025 Tue Jun 17 22:04:33 EDT 2025 Tue Jun 10 21:01:38 EDT 2025 Fri Jun 27 05:47:30 EDT 2025 Fri Jun 27 05:33:43 EDT 2025 Thu May 22 21:23:41 EDT 2025 Mon Jul 21 06:06:31 EDT 2025 Thu Apr 24 23:06:15 EDT 2025 Tue Jul 01 01:43:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c691t-3e48c85fe0898d6158991a52fc8dfe968bb76f843c7707b4695c0fed802827653 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: KM RJH. Performed the experiments: TB JS RJH. Analyzed the data: TB JS SZ RJH. Contributed reagents/materials/analysis tools: RJH. Wrote the paper: JH KM RJH. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0013082 |
| PMID | 20927340 |
| PQID | 1318921172 |
| PQPubID | 1436336 |
| PageCount | e13082 |
| ParticipantIDs | plos_journals_1318921172 doaj_primary_oai_doaj_org_article_7cb49c8e607048b6988e823604d193d2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2948015 proquest_miscellaneous_757176006 proquest_journals_1318921172 gale_infotracmisc_A473856347 gale_infotracacademiconefile_A473856347 gale_incontextgauss_ISR_A473856347 gale_incontextgauss_IOV_A473856347 gale_healthsolutions_A473856347 pubmed_primary_20927340 crossref_primary_10_1371_journal_pone_0013082 crossref_citationtrail_10_1371_journal_pone_0013082 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-09-30 |
| PublicationDateYYYYMMDD | 2010-09-30 |
| PublicationDate_xml | – month: 09 year: 2010 text: 2010-09-30 day: 30 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2010 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | 18487530 - Radiology. 2008 Jun;247(3):608-12 11407876 - Clin Nutr. 2001 Jun;20(3):271-3 5033393 - J Biol Chem. 1972 Jun 25;247(12):3858-63 20686642 - Curr Med Chem Immunol Endocr Metab Agents. 2004 Dec;4(4):349-369 17650553 - Eur Radiol. 2007 Mar;17 Suppl 2:B2-6 18940253 - Eur J Pharm Biopharm. 2009 Jun;72(2):397-404 9577506 - Radiology. 1998 May;207(2):529-38 19025903 - Magn Reson Med. 2008 Dec;60(6):1353-61 16075070 - Chem Commun (Camb). 2005 Aug 21;(31):3915-7 7534860 - Magn Reson Imaging. 1995;13(1):31-7 1394121 - Cancer Res. 1992 Oct 1;52(19):5135-43 |
| References_xml | – reference: 17650553 - Eur Radiol. 2007 Mar;17 Suppl 2:B2-6 – reference: 19025903 - Magn Reson Med. 2008 Dec;60(6):1353-61 – reference: 5033393 - J Biol Chem. 1972 Jun 25;247(12):3858-63 – reference: 20686642 - Curr Med Chem Immunol Endocr Metab Agents. 2004 Dec;4(4):349-369 – reference: 18940253 - Eur J Pharm Biopharm. 2009 Jun;72(2):397-404 – reference: 7534860 - Magn Reson Imaging. 1995;13(1):31-7 – reference: 1394121 - Cancer Res. 1992 Oct 1;52(19):5135-43 – reference: 18487530 - Radiology. 2008 Jun;247(3):608-12 – reference: 11407876 - Clin Nutr. 2001 Jun;20(3):271-3 – reference: 16075070 - Chem Commun (Camb). 2005 Aug 21;(31):3915-7 – reference: 9577506 - Radiology. 1998 May;207(2):529-38 |
| SSID | ssj0053866 |
| Score | 2.2248914 |
| Snippet | Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast... Background Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for... Background Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e13082 |
| SubjectTerms | Acetic acid Animal tissues Animals Biocompatibility Biosynthesis Biotechnology/Bioengineering Cardiovascular Disorders/Coronary Artery Disease Contrast agents Contrast media Contrast Media - administration & dosage Contrast Media - chemistry Diethylenetriamine pentaacetic acid Drug approval Drug delivery Drug delivery systems Drug development Drugs Electrons Fibrosis Gadolinium Gadolinium - administration & dosage Gadolinium - chemistry Image contrast Image resolution Immunology Intravenous administration Kidneys Lipids Liver Lymphatic system Magnetic moments Magnetic resonance Magnetic Resonance Angiography - instrumentation Magnetic Resonance Angiography - methods Magnetic resonance imaging Medical imaging Medical imaging equipment Medical treatment Metabolism Molecular weight Morphology Nanoparticles Nanoparticles - administration & dosage Nanoparticles - chemistry NMR Nuclear magnetic resonance Oncology/Hematological Malignancies Optimization Organic acids Pharmaceutical sciences Pharmacology Pharmacology/Drug Development Physiology Protein synthesis Radiology and Medical Imaging Radiology and Medical Imaging/Angiology Radiology and Medical Imaging/Magnetic Resonance Imaging Rats Renal function Safety Sensitivity Vehicles |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBLVgICTikzcOxnWNBlMKhSEBRb1bs2G2lrbNqdvn9zDhO1KBK5cA1nkTJNzOeGWX8DSFvqsY5Xbk2RfqnlLlSp5I5m8pGSwjoOQS5wPZ5wo9P2dez6uzGqC_sCRvogQfgDoTRrDbScrBNJjWvpbQ4pDtjLeQebdh9IeaNxdSwB4MXcx4PypUiP4h62V933u6Hn3WymAWiwNc_7cqL9arrb0s5_-6cvBGKjh6SBzGHpIfDu--Qe9Y_IjvRS3v6LlJJv39M1En3267o55b6xkN5HLvgqPUXqG069qHS0LHe9BsKOSxFCuMUyvBolfSqOfd41pHiNR9uvLwK042ekNOjTz8_HqdxpEJqeJ1v0tIyaWTlbCZr2UI2A-VW3lSFM7J1tuZSa8GdZKURIhMaaufKZM62EkszwavyKVl4AHGX0DZjTBdMmyLTrCycrBoB9QkkgJqZ0rQJKUd8lYl84zj2YqXCTzQBdccAl0KtqKiVhKTTXeuBb-MO-Q-oukkW2bLDBbAhFVFVd9lQQl6h4tVw9HTyeXXIkOuHl0wk5HWQQMYMjy05582279WXb7_-QejH95nQ2yjkOoDDNPEYBHwTMnHNJJczSfB7M1veRTMdUekBo1zWUM8L-J7laLq3L9NpGR-KbXbedtteiQqqe0iBeUKeDYY-AQtOhkxIWULEzAVmyM9X_OVF4CsvauQoqp7_D1W9IPeH_g3s2FmSxeZ6a_cgLdzol2EH-AMhGV8S priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZguXBBlFcDBSyEBBzS5uHYzgkV1G2LRJGAVr1ZsWNvKy3JdrPb38-M4w0EVcA1HkfJvDxjj78h5HVROacLV8cI_xQzl-tYMmdjWWkJC3oKi5xH-zzhR6fs03lxHjbculBWufGJ3lHXrcE98r0UlK-EbEVk7xdXMXaNwtPV0ELjNrmTwkqDJV1yerjxxGDLnIfrcrlI94J0dhdtY3f9kZ3MRsuRR-0ffPNkMW-7mwLPP-snf1uQpvfJvRBJ0v1e9Fvklm0ekK1gqx19GwCl3z0k6qS9tnN6WFPwpZAkh1o4etBcoMzpWahGpQhVtay6FYVIlmIFSIy7-71u0s_VrMEbjxSfNX7i8Q_f4-gROZ0efP94FIfGCrHhZbqKc8ukkYWziSxlDTENJF1pVWTOyNrZkkutBXeS5UaIRGjIoAuTOFtLTNAEL_LHZNIAE7cJrRPGdMa0yRLN8szJohKQpUAYqJnJTR2RfMNfZQLqODa_mCt_lCYg--jZpVAqKkglIvEwa9GjbvyD_gOKbqBFzGz_oF3OVOCqEkaz0kjLwcsxqXkppcV27wmrIYqt4SUvUfCqv4A6WL7aZ4j4w3MmIvLKUyBuRoOFObNq3XXq-MvZfxB9-zoiehOIXAvsMFW4DAH_hHhcI8qdESVYvxkNb6OabrjSqV92AjM3qnvzMB2G8aVYbNfYdt0pUUCOD4Ewj8iTXtEHxmZJiXhISUTEyARGnB-PNJcXHrU8KxGpqHj69696Ru729RlYkbNDJqvl2j6HsG-lX3jb_gneBlak priority: 102 providerName: ProQuest |
| Title | Novel Gd Nanoparticles Enhance Vascular Contrast for High-Resolution Magnetic Resonance Imaging |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20927340 https://www.proquest.com/docview/1318921172 https://www.proquest.com/docview/757176006 https://pubmed.ncbi.nlm.nih.gov/PMC2948015 https://doaj.org/article/7cb49c8e607048b6988e823604d193d2 http://dx.doi.org/10.1371/journal.pone.0013082 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdG98ILYnytUIqFkICHVEnjxM4DQtvUbkNaQYNOe4tix-6QSlKaFsF_z53jRAQVgXjJQ3wXKee78519_h0hL6LMGBmZ3EP4J4-ZUHqCGe2JTApY0ANY5Cza5yw-m7N319H1Hml6tjoBVjtTO-wnNV8vR9-__ngLBv_Gdm3gQcM0WpWFHtmjOAFOeR_WJo49DS5Ye64A1h3H7gLdnzgRHthPEPXF76xVFtK_ddy91bKsdkWlvxdX_rJaTe-SOy7MpEe1XhyQPV3cIwfOkCv6yqFNv75P0ln5TS_paU7B0UIG7Qrl6KS4QYWgV65UlSKO1TqrNhTCXIrlIR5u_deKSy-yRYHXISm-Kyzj-RfbAOkBmU8nn07OPNd1wVNxEmy8UDOhRGS0LxKRQ8ADGVmQRWOjRG50EgspeWwECxXnPpeQXkfKNzoXmL3xOAofkl4B8jwkNPcZk2Mm1diXLBwbEWUcUhiIESVTocr7JGzkmyoHSY6dMZapPWfjkJrU4kpxglI3QX3itVyrGpLjL_THOHUtLQJq2xflepE6qaZcSZYooWNwgUzIOBFCYy94n-UQ4ubwkWc48Wl9O7V1C-kRQzigOGS8T55bCgTVKLBqZ5Ftqyo9f3_1D0QfLztELx2RKUEcKnM3JeCfEKyrQznoUIJrUJ3hQ1TTRioVyCgQCaT8HP5n0Kju7mHaDuNHsRKv0OW2SnnEAzzMjfvkUa3orWAbs-kT3jGBjuS7I8XnGwtpPk4Qxih6_N-cT8jtuq4DK3kGpLdZb_VTCBc3ckhu8WsOT3ES4HN6OiT7x5PZh8uh3YAZWg_xE1aibu4 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELem8gAviPG1wmAWAgEP2fLhxM4DQgPWtWwrEmzT3kzs2B1SSUrTgvin-Bu5S5xC0AS87DU-R-35fB-5u98R8jjOrFWxzT2Ef_KYjZQnmDWeyJQAgx6AkavRPsfJ8IS9PYvP1siPthcGyypbnVgr6rzU-I18JwDhSyFa4eHL2RcPp0ZhdrUdodGIxYH5_g1CturF6A2c75MwHOwdvx56bqqAp5M0WHiRYUKL2BpfpCIHgw4RR5DFodUityZNhFI8sYJFmnOfKwgfY-1bkwuMTniCUyJA5V9hEVhy7Ewf7LeaH3RHkrj2vIgHO04atmdlYbbrFKEIO-avnhKwsgW92bSsLnJ0_6zX_M0ADm6Q685zpbuNqK2TNVPcJOtON1T0mQOwfn6LyHH51Uzpfk5Bd0NQ7mrv6F5xjjJGT131K0VorHlWLSh4zhQrTjzMJjR3gR5lkwI7LCk-K-qNo8_1TKXb5ORSWH6H9Apg4gahuc-YCpnSoa9YFFoRZxyiInA7FdORzvskavkrtUM5x2EbU1mn7jhEOw27JJ6KdKfSJ95q16xB-fgH_Ss8uhUtYnTXD8r5RDquSq4VS7UwCWhVJlSSCmFwvLzPcvCac3jJFh68bBpeV5pG7jJEGEoixvvkUU2BOB0FFgJNsmVVydG70_8g-vC-Q_TUEdkS2KEz13wB_wnxvzqUmx1K0Da6s7yBYtpypZK_7iXsbEX34mW6WsaXYnFfYcplJXnMA8wPJ31ytxH0FWNDP0X8Jb9PeOcKdDjfXSk-ndco6WGKyEjxvb__qi1ydXh8dCgPR-OD--RaUxuC1UCbpLeYL80DcDkX6mF9zyn5eNmK5SdDDpJS |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIiFeEONrhcEsBAIesubDiZ0HhMa2sjIoCNi0Ny927A6pJKVpQfxr_HXcJW4gaAJe9hqfo_Z8_t1dfP4dIQ_jzFoV29xD-ieP2Uh5glnjiUwJcOgBOLma7XOcHByxVyfxyRr5sboLg2WVK0ysgTovNX4jHwRgfClkKzwcWFcW8W5v-Hz2xcMOUnjSumqn0ZjIofn-DdK36tloD9b6URgO9z_uHniuw4CnkzRYeJFhQovYGl-kIgfnDtlHkMWh1SK3Jk2EUjyxgkWac58rSCVj7VuTC8xUeIIdIwD-L_GIC9xjYrctLwEcSRJ3VS_iwcBZxvasLMx2fVwowo4rrDsGtH6hN5uW1XlB75-1m785w-E1ctVFsXSnMbt1smaK62Td4URFnzgy66c3iByXX82Uvswp4Dgk6K4Oj-4XZ2hv9NhVwlKkyZpn1YJCFE2x-sTDk4VmX9A32aTA25YUnxX1xNHnur_STXJ0ISq_RXoFKHGD0NxnTIVM6dBXLAqtiDMOGRKEoIrpSOd9Eq30K7VjPMfGG1NZH-NxyHwadUlcFelWpU-8dtasYfz4h_wLXLpWFvm66wflfCKdViXXiqVamAQQlgmVpEIYbDXvsxwi6BxesoULL5vLry3qyB2GbENJxHifPKglkLOjQOufZMuqkqO3x_8h9OF9R-ixE7IlqENn7iIG_CfkAutIbnYkAXl0Z3gDzXSllUr-2qMwc2W65w_TdhhfioV-hSmXleQxD_CsOOmT242ht4oN_RS5mPw-4Z0t0NF8d6T4dFYzpocpsiTFd_7-q7bIZYAU-Xo0PrxLrjRlIlgYtEl6i_nS3IPoc6Hu19ucktOLxpWfvRqWUw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+Gd+Nanoparticles+Enhance+Vascular+Contrast+for+High-Resolution+Magnetic+Resonance+Imaging&rft.jtitle=PloS+one&rft.au=Bui%2C+Tot&rft.au=Stevenson%2C+Jeff&rft.au=Hoekman%2C+John&rft.au=Zhang%2C+Shanrong&rft.date=2010-09-30&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=5&rft.issue=9&rft_id=info:doi/10.1371%2Fjournal.pone.0013082&rft_id=info%3Apmid%2F20927340&rft.externalDocID=PMC2948015 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |